CA2734135C - Inhalateur de pmdi comprenant du fluticasone et du salmeterol - Google Patents
Inhalateur de pmdi comprenant du fluticasone et du salmeterol Download PDFInfo
- Publication number
- CA2734135C CA2734135C CA2734135A CA2734135A CA2734135C CA 2734135 C CA2734135 C CA 2734135C CA 2734135 A CA2734135 A CA 2734135A CA 2734135 A CA2734135 A CA 2734135A CA 2734135 C CA2734135 C CA 2734135C
- Authority
- CA
- Canada
- Prior art keywords
- link
- pmdi
- flap
- inhaler
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 229960002714 fluticasone Drugs 0.000 title claims abstract description 15
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 title claims abstract description 15
- 229960004017 salmeterol Drugs 0.000 title claims abstract description 13
- 230000007246 mechanism Effects 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 208000006673 asthma Diseases 0.000 claims abstract description 12
- 238000009472 formulation Methods 0.000 claims abstract description 10
- 239000000443 aerosol Substances 0.000 claims description 14
- 229960000289 fluticasone propionate Drugs 0.000 claims description 9
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 9
- 229960005018 salmeterol xinafoate Drugs 0.000 claims description 7
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 description 26
- 239000012530 fluid Substances 0.000 description 24
- 239000000428 dust Substances 0.000 description 18
- 230000033001 locomotion Effects 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 14
- 230000008021 deposition Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 210000000629 knee joint Anatomy 0.000 description 8
- 229940071648 metered dose inhaler Drugs 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940125389 long-acting beta agonist Drugs 0.000 description 7
- 239000003246 corticosteroid Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001078 anti-cholinergic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940125390 short-acting beta agonist Drugs 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 3
- 229940110309 tiotropium Drugs 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940125369 inhaled corticosteroids Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000237983 Trochidae Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229940080593 budesonide / formoterol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229940114006 fluticasone / salmeterol Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
- A61M15/0026—Hinged caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
- A61M15/0073—Mechanical counters having a display or indicator on a ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
- A61M15/0075—Mechanical counters having a display or indicator on a disc
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/008—Electronic counters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
- A61M15/0093—Inhalators mechanically breath-triggered without arming or cocking, e.g. acting directly on the delivery valve
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention porte sur des inhalateurs doseurs destinés à l'administration de médicaments actifs/propulseurs et excipients à partir de canettes d'aérosol sous pression. L'invention porte sur un inhalateur de pMDI (20) comprenant une canette de pMDI (22), un dispositif de tourbillon, un avertisseur sonore intégré (58) et un mécanisme activé par la respiration (26, 28, 34, 66, 78), la canette (22) contenant une formulation renfermant une combinaison de deux ingrédients actifs ou plus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0812854.8 | 2008-07-14 | ||
GB0812854.8A GB2461752B (en) | 2008-07-14 | 2008-07-14 | Metered dose inhaler |
PCT/GB2009/001740 WO2010007361A1 (fr) | 2008-07-14 | 2009-07-14 | Inhalateur doseur |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2734135A1 CA2734135A1 (fr) | 2010-01-21 |
CA2734135C true CA2734135C (fr) | 2020-12-29 |
Family
ID=39722250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2734135A Active CA2734135C (fr) | 2008-07-14 | 2009-07-14 | Inhalateur de pmdi comprenant du fluticasone et du salmeterol |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2313113A1 (fr) |
CA (1) | CA2734135C (fr) |
GB (1) | GB2461752B (fr) |
NZ (1) | NZ591174A (fr) |
WO (1) | WO2010007361A1 (fr) |
ZA (1) | ZA201101206B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2534957B1 (fr) | 2007-12-14 | 2015-05-27 | AeroDesigns, Inc | Administration de produits sous forme d'aérosols |
JP4878651B1 (ja) * | 2010-09-17 | 2012-02-15 | シャープ株式会社 | 移動局装置、通信システム、通信方法および集積回路 |
GB201118845D0 (en) | 2011-11-01 | 2011-12-14 | Euro Celtique Sa | Dispenser |
EP2983773B1 (fr) | 2013-03-14 | 2018-03-07 | Trudell Medical International | Applicateur pour inhalateur doseur |
US20160213688A1 (en) * | 2015-01-23 | 2016-07-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament |
GB2544477A (en) * | 2015-11-16 | 2017-05-24 | 3M Innovative Properties Co | Improvements in or relating to medical actuators |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0194257A1 (fr) * | 1984-09-18 | 1986-09-17 | Vortran Corporation | Dispositif de production d'aerosol |
EP0308524B1 (fr) * | 1987-09-22 | 1995-04-26 | Vortran Medical Technology, Inc. | Dispositif d'inhalation et méthode |
US4955371A (en) * | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
US6119688A (en) * | 1991-08-26 | 2000-09-19 | 3M Innovative Properties Company | Powder dispenser |
IL106930A0 (en) * | 1992-09-08 | 1993-12-28 | Norton Healthcare Ltd | Medicament dispensing device |
JP4056740B2 (ja) * | 1999-10-16 | 2008-03-05 | グラクソ グループ リミテッド | エアゾール容器のための装置のハウジング |
US6581590B1 (en) * | 2000-03-21 | 2003-06-24 | Iep Pharmaceutical Devices Inc. | Inhalation actuated device |
PE20020066A1 (es) * | 2000-06-23 | 2002-02-23 | Norton Healthcare Ltd | Deposito de dosis medidas previamente para inhalador de polvo seco accionado por la respiracion |
CN100398094C (zh) * | 2002-03-01 | 2008-07-02 | 奇斯药制品公司 | 福莫特罗超细制剂 |
SE0301426D0 (sv) * | 2003-05-15 | 2003-05-15 | Astrazeneca Ab | Novel treatment |
US7600512B2 (en) * | 2003-07-14 | 2009-10-13 | Vortran Medical Technology 1, Inc. | Inhaler with breath actuated dose counter |
US7703454B2 (en) * | 2003-07-14 | 2010-04-27 | Vortran Medical Technology | Inhaler with breath actuated dose counter |
US7219664B2 (en) * | 2005-04-28 | 2007-05-22 | Kos Life Sciences, Inc. | Breath actuated inhaler |
GB0518770D0 (en) * | 2005-09-14 | 2005-10-26 | Glaxo Group Ltd | A closure for a dispensing device |
AR058290A1 (es) * | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Dispensador de medicamento |
GB0602897D0 (en) * | 2006-02-13 | 2006-03-22 | Jagotec Ag | Improvements In Or Relating To Dry Powder Inhaler Devices |
GB0611131D0 (en) * | 2006-06-06 | 2006-07-19 | Neo Inhalation Technologies Lt | Nicotine inhalation therapies - smoking cessation and other medical uses |
HUE034380T2 (en) * | 2007-04-30 | 2018-02-28 | Sun Pharma Advanced Res Co Ltd | Inhalation device |
-
2008
- 2008-07-14 GB GB0812854.8A patent/GB2461752B/en active Active
-
2009
- 2009-07-14 EP EP09784697A patent/EP2313113A1/fr not_active Withdrawn
- 2009-07-14 WO PCT/GB2009/001740 patent/WO2010007361A1/fr active Application Filing
- 2009-07-14 NZ NZ591174A patent/NZ591174A/xx active Application Filing
- 2009-07-14 CA CA2734135A patent/CA2734135C/fr active Active
-
2011
- 2011-02-15 ZA ZA2011/01206A patent/ZA201101206B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB2461752A (en) | 2010-01-20 |
NZ591174A (en) | 2013-09-27 |
WO2010007361A1 (fr) | 2010-01-21 |
EP2313113A1 (fr) | 2011-04-27 |
GB0812854D0 (en) | 2008-08-20 |
GB2461752B (en) | 2013-04-17 |
CA2734135A1 (fr) | 2010-01-21 |
ZA201101206B (en) | 2012-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7600512B2 (en) | Inhaler with breath actuated dose counter | |
CA2532797C (fr) | Inhalateur actionne par la respiration | |
CA2734135C (fr) | Inhalateur de pmdi comprenant du fluticasone et du salmeterol | |
JP4497730B2 (ja) | 複合薬剤用の粉末吸入器 | |
ES2871820T3 (es) | Inhalador de polvo seco | |
AU2019222959B2 (en) | Dry powder inhaler and inhalation actuated mechanism thereof | |
US20190275269A1 (en) | Dry Powder Inhaler | |
CN109689139B (zh) | 用于吸入器的触发机构 | |
WO2007141520A1 (fr) | Thérapies par inhalation de nicotine – pour arrêter de fumer et pour autres utilisations médicales | |
PL182715B1 (pl) | Inhalator sproszkowanych lekarstw | |
CN109689140B (zh) | 用于吸入器的触发机构 | |
US20140158126A1 (en) | Drug delivery device for the treatment of patients with respiratory diseases | |
TWI590846B (zh) | 可吸入式藥劑 | |
WO2009029028A1 (fr) | Inhalateur à enclenchement respiratoire équipé d'un compteur de dose | |
AU2013204795B2 (en) | Inhaler with breath actuated dose counter | |
RU2258539C1 (ru) | Порошковый ингалятор | |
WO2023117929A1 (fr) | Inhalateur de poudre | |
CN116672549A (zh) | 准纳器 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20140609 |